Australian Patient Achieves Remarkable Early Response with BIOOCUS Medical Group’s Dual CD19/CD20 CAR-T Therapy for Relapsed DLBCL

Rodney Charles Monger, a 68-year-old gentleman from Australia, was diagnosed with diffuse large B-Cell Lymphoma (DLBCL) three years prior. Seeking advanced care, he turned to BIOOCUS Medical Group in August 2025. A cervical lymph node biopsy confirmed invasive B-cell lymphoma of germinal center origin. Immunohistochemistry was strongly positive for CD20, CD19, and CD10, with high expression of Bcl-6, Bcl-2 (70%+), and c-MYC (60%+). Genetic testing revealed BCL2 rearrangement by FISH and mutations in EZH2, KMT2D, TNFRSF14, NRAS, and TPMT genes—clear markers of an aggressive, high-risk profile.

After receiving pola combined with a BTK inhibitor and lenalidomide, followed by FC lymphodepletion chemotherapy, Mr. Monger’s disease remained refractory. The team at BIOOCUS Medical Group recommended their innovative dual-targeting CD19/CD20 CAR-T cell therapy.

On September 8, 2025, Mr. Monger received the infusion of autologous CD19/CD20 CAR-T cells. Remarkably, he experienced no cytokine release syndrome (CRS) and no immune effector cell-associated neurotoxicity syndrome (ICANS), resulting in a smooth post-infusion course that kept him stable and optimistic from day one.

Peripheral blood monitoring documented impressive CAR-T cell expansion, confirming excellent engraftment and proliferation. On day 4 post-infusion, CAR19+ cells were 0.50% of CD3+ T cells (absolute value 6.04 × 10⁷/L) and CAR20+ cells 0.41% (4.96 × 10⁷/L). By day 7, CAR19+ rose to 1.68% (1.40 × 10⁷/L) and CAR20+ to 1.63% (1.36 × 10⁷/L). On day 10, CAR19+ reached 31.43% of CD3+ T cells (absolute value 3.13 × 10⁸/L) and CAR20+ reached 32.74% (absolute value 3.26 × 10⁸/L). Flow cytometry further showed balanced distribution across CD4+ and CD8+ subsets with strong dual CAR expression, illustrating the therapy’s ability to promote robust in-vivo persistence and proliferation.

At the latest follow-up (day 10), Mr. Monger continues to do well clinically. He is on a tailored oral medication regimen including acyclovir, compound sulfamethoxazole, orelabrutinib, lenalidomide, and supportive agents, with regular monitoring of blood counts, liver and kidney function, and inflammatory markers.

The BIOOCUS Medical Group team provided comprehensive, patient-centered support throughout, including comfortable accommodation, nutritious meals, transportation assistance, and psychological counseling for Mr. Monger and his family. This holistic approach allowed him to focus fully on recovery.

Mr. Monger’s case exemplifies the transformative potential of BIOOCUS Medical Group’s dual CD19/CD20 CAR-T therapy for patients with relapsed/refractory DLBCL. The rapid, robust expansion of CAR-T cells without severe toxicities highlights the product’s favorable safety profile and potent anti-tumor activity—even in an older patient with high-risk molecular features.